Cytek Biosciences Inc (NAS:CTKB)
$ 6.39 -0.14 (-2.14%) Market Cap: 841.13 Mil Enterprise Value: 572.72 Mil PE Ratio: 0 PB Ratio: 2.20 GF Score: 60/100

Cytek Biosciences Inc at Morgan Stanley Global Healthcare Conference Transcript

Sep 13, 2023 / 08:15PM GMT
Release Date Price: $7.26 (+0.55%)
Yih;Ming Tu
Morgan Stanley, Research Division - Research Associate

Good afternoon, everyone. Welcome to day 3 of our Morgan Stanley Global Healthcare Conference. My name is Edmund Tu. I work on the life science tools team here at MS.

Before we begin, I want to remind everyone important disclosures can be found at morganstanley.com/researchdisclosures. And it's my pleasure to be hosting Cytek Biosciences today. And on-stage representing the company, I have Wenbin Jiang, CEO; and Patrik Jeanmonod, CFO. Thank you guys for coming and welcome.

Wenbin Jiang
Cytek Biosciences, Inc. - President, CEO & Chairman of the Board

Thank you.

Patrik Sebastian Jeanmonod
Cytek Biosciences, Inc. - CFO

Thank you.

Questions & Answers

Yih;Ming Tu
Morgan Stanley, Research Division - Research Associate

I guess to start, Wenbin. Can you talk about what you think is Cytek's key accomplishments over the past 12 months? What were some

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot